FDA 510(k)
FDA class 2
Substantially Equivalent
🇺🇸 United States
23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
K Number: K221885
·
Decision Oct 26, 2022
Classifications
1
FEI Numbers
1
Registration Numbers
1
Same Product Code
2
Applicant Total
8
Review Days
119
Research this 510(k) in seconds
The Research Assistant summarizes clearance history, predicates and product-code trends — and cites every record.
Free to try · every answer cites its records
Basic Information
- Device Name
- 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
- K Number
- K221885
- Device Class
- FDA class 2
- Clearance Type
- Traditional
- Regulation Number
- 862.3364
- Medical Specialty
- Medical Genetics
- Decision
- Substantially Equivalent
- Statement or Summary
- Summary
- Applicant
- 23AndMe, Inc.
- Date Received
- June 29, 2022
- Decision Date
- October 26, 2022
- Product Code
- QDJ
- Advisory Committee
- Medical Genetics
- Review Advisory Committee
- CH
- Third Party
- N
Classifications
This FDA 510(k) entry is associated with 1 FDA classification via its product code.
| Product Code | Device Name | Device Class | Medical Specialty |
|---|---|---|---|
| QDJ | Direct-To-Consumer Access Pharmacogenetic Assessment System | FDA class 2 | Medical Genetics |
Similar 510(k) Clearances
Other 510(k) clearances with the same product code (QDJ), ordered by most recent decision date.
23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
FDA 510(k)
FDA Class 2
·Medical Genetics
23andMe Personal Genome Service (PGS) Pharmacogenetic Reports
FDA 510(k)
FDA Class 2
·Medical Genetics
Other Clearances by 23AndMe, Inc.
| K Number | Device Name | ||
|---|---|---|---|
| K223597 | 23andMe® Personal Genome Service® (PGS®) Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) | Aug 31, 2023 | Substantially Equivalent |
| K211499 | 23andMe PGS Genetic Risk Report for Hereditary Prostate Cancer (HOXB13-Related) | Jan 6, 2022 | Substantially Equivalent |
| K193492 | 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports | Aug 17, 2020 | Substantially Equivalent |
| K182784 | MUTYH-Associated Polyposis (MAP) | Jan 18, 2019 | Substantially Equivalent |
| DEN180028 | 23andMe Personal Genome Service (PGS) Pharmacogenetic Reports | Oct 31, 2018 | Unknown |
| DEN170046 | 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) | Mar 6, 2018 | Unknown |
| DEN160026 | 23andMe Personal Genome Service (PGS) Genetic Health Risk Test for Hereditary Thrombophilia | Apr 6, 2017 | Unknown |